查看購物車
  • English
  • Japanese
  • Korean
合約開發和生產組織 (CDMO) 市場 - 全球和區域分析：按服務、產品類型、應用、最終用戶和地區分類 - 分析和預測，2026-2036 年
市場調查報告書
商品編碼
2125003

合約開發和生產組織 (CDMO) 市場 - 全球和區域分析：按服務、產品類型、應用、最終用戶和地區分類 - 分析和預測，2026-2036 年

Contract Development and Manufacturing Organization (CDMO) Market - A Global and Regional Analysis: Focus on Service, Product Type, Application, End User, and Region - Analysis and Forecast, 2026-2036
出版日期: | 出版商: BIS Research | 英文 216 Pages | 商品交期: 1-5個工作天內

價格

全球合約開發和生產組織 (CDMO) 市場最初估計在 2025 年的價值為 2498 億美元，但預計從 2026 年到 2036 年將以 8.26% 的複合年成長率大幅成長，到 2036 年達到 5931 億美元。

關鍵市場統計數據
預測期 2026-2036
2026年市場規模 2683億美元
2036年的預測 5931億美元
複合年成長率 8.26%

全球合約開發與生產組織 (CDMO) 市場正穩步成長，這主要得益於製藥、生物技術、醫療設備和生命科學價值鏈中外包業務的不斷成長。 CDMO 提供產品開發、製程最佳化、分析測試、臨床和商業化生產、無菌填充和包裝、組件製造、設備組裝、成品生產和包裝等外包服務。推動該市場成長的因素包括：製藥和生物製藥產品線的擴展、產品複雜性的增加、對專業化生產能力的需求不斷成長、研發週期縮短以及企業為減少自有設施的資本投入而做出的努力。製藥 CDMO 服務是最大的服務細分市場，反映了對製劑和製程開發、分析測試、臨床規模生產、商業規模生產、無菌填充和包裝以及藥品包裝的持續需求。隨著目的地設備製造商 (OEM) 擴大將產品設計、工程、原型製作、組件製造、組裝、測試、驗證和成品生產外包，醫療設備CDMO 服務的重要性日益凸顯。此外，該市場還包括生命科學工具和研究產品的合約開發和生產。

市場概覽

全球合約研發生產機構 (CDMO) 市場指的是為製藥、生物技術、醫療設備和生命科學公司提供研發和生產外包服務的第三方服務供應商。該市場涵蓋了產品整個生命週期中合約研發、製程最佳化、分析測試、臨床和商業化生產、無菌填充和包裝、組件製造、設備組裝、成品製造和包裝等環節所產生的收入。

隨著外包關係從簡單的生產合約轉向策略性和一體化的開發到商業化夥伴關係，市場發生了顯著變化。製藥和生物技術公司利用CDMO（合約研發生產機構）來發揮其在配方、製程開發、分析、生物製藥生產、高活性化合物合成、先進醫療技術和無菌加工方面的能力。醫療設備製造商則利用CDMO進行產品工程、設計轉移、原型製作、精密製造、電子整合、無塵室組裝、測試、驗證和商業化生產。

該市場日益受到整合式端到端服務平台、長期合約、雙源區域製造網路、模組化設施、一次性技術、自動化、流程分析技術、人工智慧、數位孿生和先進製造系統的影響。這些能力使合約研發生產機構 (CDMO) 能夠實現跨多個地點的技術轉移、生產柔軟性、供應連續性、批次監控、品管和營運效率的提升。

在這個市場運作的公司正著重關注技術專長、法規遵循、生產規模、產能運轉率、地域覆蓋範圍、供應鏈韌性、技術轉移速度以及從早期研發到商業化生產的產品支援能力。隨著製藥、生物技術和醫療設備公司繼續優先考慮最小資產商業模式，專業化和一體化的合約研發生產機構（CDMO）預計將在全球醫療保健和生命科學供應鏈中扮演日益重要的角色。

對產業的影響

全球合約研發生產機構 (CDMO) 市場正在擴張，這主要得益於製藥和醫療設備業對專業研發技術、靈活生產能力、標準化生產以及快速上市的需求不斷成長。 Lonza、Thermo Fisher Scientific、Catalent、Samsung Biologics、Boehringer Ingelheim International、Recipharm、Siegfried Holding、Piramal Pharma、Corden Pharma、AGC、Molex、Integer Holdings、Jabil、Sanmina 和 Quasar Medical 等領先企業在提升研發和生產能力方面發揮著至關重要的作用。

這些公司為小分子藥物、生物製藥、無菌製劑、疫苗、胜肽類藥物、寡核苷酸、抗體藥物複合體(ADC)、細胞和基因療法、外科和介入性醫療設備、植入、體外診斷醫療設備、給藥系統、病患監測設備以及生命科學研究產品提供支援。 CDMO 透過提供整合的開發、技術轉移、生產、測試、組裝、填充和包裝服務，幫助產品製造商降低資本需求、利用專業基礎設施、提高生產柔軟性並加速從臨床開發到商業化供應的過渡。

該市場對那些正在拓展產品線但專業生產能力有限的製藥和生技公司影響最為顯著。醫療設備製造商也越來越依賴合約研發生產機構（CDMO）來取得精密組件、複雜組裝、電子整合、無塵室生產和成品製造服務。然而，監管整改措施、品質體係不完善、產能與需求不平衡、贊助商資金籌措、供應鏈中斷以及高昂的固定營運成本等問題，持續影響產能利用率與商業性績效。

目錄

第1章：全球合約研發生產組織（CDMO）市場：產業展望

  • 市場概覽與生態系統
    • 介紹
    • 外包的演變
    • CDMO在價值鏈中的作用
  • 市場趨勢
    • 趨勢：對當前和未來影響的評估
  • 供應鏈分析
  • 監理情勢
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇

第2章：2024-2036年全球合約開發與生產組織（CDMO）市場（依服務分類）

  • 醫藥CDMO服務
    • 市場規模及預測
    • 醫藥合約開發服務
    • 藥品契約製造服務
  • 醫療設備CDMO服務
    • 市場規模及預測
    • 醫療設備合約開發服務
    • 醫療設備契約製造服務
  • 其他
    • 市場規模及預測

第3章：2024-2036年全球合約開發與生產組織（CDMO）市場（依產品類型分類）

  • 製藥
    • 市場規模及預測
    • 小分子藥物
    • 生物製藥
  • 醫療設備
    • 市場規模及預測
    • 外科和介入醫療設備
    • 植入式醫療設備
    • 體外診斷醫療設備（IVD）
    • 藥物輸送裝置
    • 病患監測及診斷醫療設備
  • 其他
    • 市場規模及預測

第4章：2024-2036年全球合約開發與生產組織（CDMO）市場（依應用領域分類）

  • 製藥
    • 市場規模及預測
    • 腫瘤學
    • 感染疾病
    • 心血管疾病
    • 神經病學
    • 代謝性疾病
    • 免疫學
    • 罕見疾病
    • 其他
  • 醫療設備
    • 市場規模及預測
    • 循環系統
    • 整形外科
    • 糖尿病
    • 神經病學
    • 消化系統
    • 腫瘤學
    • 眼科
    • 其他
  • 其他用途
    • 市場規模及預測

第5章：2024-2036年全球合約開發與生產組織（CDMO）市場（依最終用戶分類）

  • 學術和研究機構
    • 市場規模及預測
  • 製藥公司
    • 市場規模及預測
  • 生技公司
    • 市場規模及預測
  • 醫療設備製造商
    • 市場規模及預測
  • 其他最終用戶
    • 市場規模及預測

第6章：2024-2036年全球合約開發與生產組織（CDMO）市場（按地區分類）

  • 區域概況
  • 北美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 歐洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 亞太地區
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 拉丁美洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
  • 中東和非洲
    • 區域概覽
    • 市場成長促進因素
    • 市場挑戰
    • 分析師意見
    • 市場規模及預測
    • 沙烏地阿拉伯
    • 埃及
    • 其他中東和非洲地區

第7章：競爭標竿分析與公司概況

  • 關鍵策略和趨勢
  • 公司簡介
    • Lonza
    • Thermo Fisher Scientific Inc.
    • Catalent, Inc.
    • Samsung Biologics
    • Boehringer Ingelheim GmbH
    • Recipharm AB
    • Siegfried Holding AG
    • Piramal Pharma Limited
    • CordenPharma
    • AGC Group
    • Molex
    • Integer Holdings Corporation
    • Jabil Inc.
    • Sanmina Corporation
    • Quasar

第8章：調查方法

This report can be delivered within 1 working day.

Introduction of the Contract Development and Manufacturing Organization (CDMO) Market

The global contract development and manufacturing organization (CDMO) market, initially valued at $249.8 billion in 2025, is projected to grow substantially, reaching $593.1 billion by 2036, with a compound annual growth rate (CAGR) of 8.26% from 2026 to 2036.

KEY MARKET STATISTICS
Forecast Period2026 - 2036
2026 Evaluation$268.3 Billion
2036 Forecast$593.1 Billion
CAGR8.26%

The global contract development and manufacturing organization (CDMO) market has been experiencing steady growth, driven by increasing outsourcing across pharmaceutical, biotechnology, medical-device, and life-science value chains. CDMOs provide outsourced product development, process optimization, analytical testing, clinical and commercial manufacturing, sterile fill-finish, component manufacturing, device assembly, finished-product manufacturing, and packaging services. The market is supported by expanding pharmaceutical and biologics pipelines, rising product complexity, growing demand for specialized manufacturing capacity, shorter development timelines, and companies' efforts to reduce capital investment in internal facilities. Pharmaceutical CDMO services represent the largest service segment, reflecting sustained demand for formulation and process development, analytical testing, clinical-scale manufacturing, commercial-scale production, sterile fill-finish, and pharmaceutical packaging. Medical-device CDMO services are gaining importance as original equipment manufacturers increasingly outsource product design, engineering, prototyping, component production, assembly, integration, testing, validation, and finished-device manufacturing. The market also covers contract development and manufacturing of life-science tools and research-use products.

Market Introduction

The global contract development and manufacturing organization (CDMO) market represents third-party service providers offering outsourced development and manufacturing services to pharmaceutical, biotechnology, medical-device, and life-science companies. The market includes revenues generated from contract development, process optimization, analytical testing, clinical and commercial manufacturing, sterile fill-finish, component production, device assembly, finished-product manufacturing, and packaging across the product lifecycle.

The market has evolved significantly as outsourcing relationships have shifted from transactional manufacturing arrangements toward strategic and integrated development-to-commercialization partnerships. Pharmaceutical and biotechnology companies use CDMOs to access formulation, process development, analytical, biologics manufacturing, high-potency synthesis, advanced-therapy, and sterile-processing capabilities. Medical-device companies use CDMOs for product engineering, design transfer, prototyping, precision manufacturing, electronics integration, cleanroom assembly, testing, validation, and commercial-scale production.

The market is increasingly shaped by integrated end-to-end service platforms, longer-term contracts, dual-sourced regional manufacturing networks, modular facilities, single-use technologies, automation, process analytical technology, artificial intelligence, digital twins, and advanced manufacturing systems. These capabilities allow CDMOs to improve technology transfer, manufacturing flexibility, supply continuity, batch monitoring, quality control, and operational efficiency across multiple sites.

Companies operating in the market are focusing on technical expertise, regulatory compliance, manufacturing scale, capacity utilization, geographic reach, supply-chain resilience, speed of technology transfer, and the ability to support products from early development through commercial production. As pharmaceutical, biotechnology, and medical-device companies continue to prioritize asset-light operating models, specialized and integrated CDMOs are expected to become increasingly important across global healthcare and life-science supply chains.

Industrial Impact

The global contract development and manufacturing organization (CDMO) market has witnessed increasing adoption, driven by the need for specialized development expertise, flexible production capacity, regulatory-compliant manufacturing, and faster commercialization across pharmaceutical and medical-device industries. Key players such as Lonza, Thermo Fisher Scientific Inc., Catalent, Inc., Samsung Biologics, Boehringer Ingelheim International GmbH, Recipharm AB, Siegfried Holding AG, Piramal Pharma Limited, CordenPharma, AGC Inc., Molex, Integer Holdings Corporation, Jabil Inc., Sanmina Corporation, and Quasar Medical play an important role in advancing outsourced development and manufacturing capabilities.

These companies support small molecules, biologics, sterile products, vaccines, peptides, oligonucleotides, antibody-drug conjugates, cell and gene therapies, surgical and interventional devices, implants, in vitro diagnostic devices, drug-delivery systems, patient-monitoring devices, and life-science research products. By providing integrated development, technology transfer, manufacturing, testing, assembly, fill-finish, and packaging services, CDMOs enable product companies to reduce capital requirements, access specialized infrastructure, improve production flexibility, and accelerate the transition from clinical development to commercial supply.

The market's impact is most visible among pharmaceutical and biotechnology companies with expanding pipelines but limited specialized manufacturing capacity. Medical-device companies also increasingly rely on CDMOs for precision components, complex assemblies, electronics integration, cleanroom production, and finished-device manufacturing. However, regulatory remediation, quality-system failures, capacity-demand imbalances, sponsor funding constraints, supply-chain disruptions, and high fixed operating costs continue to affect utilization and commercial performance.

Market Segmentation:

Segmentation 1: By Service

  • Pharmaceutical CDMO Services
  • Medical Device CDMO Services

Pharmaceutical CDMO Services Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by Service)

In 2025, pharmaceutical CDMO services accounted for the largest market share due to sustained outsourcing across formulation development, process development, analytical testing, clinical manufacturing, commercial-scale production, sterile fill-finish, and pharmaceutical packaging. The segment is supported by expanding small-molecule and biologics pipelines, increasing demand for specialized manufacturing capacity, and pharmaceutical and biotechnology companies' efforts to reduce capital expenditure and improve development flexibility. Medical-device CDMO services are expected to register the highest growth, supported by increasing outsourcing of product engineering, prototyping, component manufacturing, device assembly, testing, and finished-device production.

Segmentation 2: By Product Type

  • Pharmaceuticals
    • Small Molecules
    • Biologics
  • Medical Devices
    • Surgical and Interventional Devices
    • Implantable Medical Devices
    • In Vitro Diagnostic Devices
    • Drug Delivery Devices
    • Patient Monitoring and Diagnostic Devices
  • Others

Small Molecules Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals (by Product Type)

In 2025, pharmaceuticals accounted for the largest product-type share, supported by extensive outsourcing of drug development, clinical manufacturing, commercial production, sterile fill-finish, and packaging. Within pharmaceuticals, small molecules represented the largest segment due to their established role in approved therapies, extensive development pipelines, mature manufacturing infrastructure, and broad demand for active pharmaceutical ingredients, intermediates, and finished dosage forms. Biologics are expected to register faster growth, supported by increasing development of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, antibody-drug conjugates, and cell and gene therapies.

Segmentation 3: By Application

  • Pharmaceuticals
    • Oncology
    • Infectious Disease
    • Cardiovascular Diseases
    • Neurology
    • Metabolic Disorders
    • Immunology
    • Rare Diseases
    • Others
  • Medical Devices
    • Cardiovascular
    • Orthopedics
    • Diabetes
    • Neurology
    • Gastroenterology
    • Oncology
    • Ophthalmology
    • Others
  • Others Application

Oncology Segment to Dominate the Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals (by Application)

In 2025, oncology accounted for the largest share of the pharmaceutical application segment due to the expanding oncology drug pipeline, increasing development of targeted therapies and biologics, and strong demand for specialized clinical and commercial manufacturing capabilities. Oncology is also expected to register the highest growth during the forecast period, supported by increasing investment in cancer research, personalized therapies, antibody-drug conjugates, high-potency compounds, biologics, and complex sterile products. Medical-device applications span cardiovascular care, orthopedics, diabetes, neurology, gastroenterology, oncology, ophthalmology, and other therapeutic areas.

Segmentation 4: By End User

  • Academic and Research Institutes
  • Pharmaceutical Companies
  • Biotechnology Companies
  • Medical Device Companies
  • Other End Users

Pharmaceutical Companies to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by End User)

In terms of end user, pharmaceutical companies are expected to lead the global Contract Development and Manufacturing Organization (CDMO) market. These companies extensively use CDMOs for small-molecule and biologics development, formulation, process optimization, analytical testing, clinical manufacturing, commercial-scale production, sterile fill-finish, packaging, and lifecycle support. Outsourcing allows pharmaceutical companies to access specialized capabilities, manage capacity fluctuations, establish secondary supply sources, reduce fixed manufacturing expenditure, and accelerate product launches. Biotechnology companies are expected to register the highest growth due to expanding biologics and advanced-therapy pipelines and their comparatively limited internal manufacturing infrastructure.

Segmentation 5: By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest-of-Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest-of-Latin America
  • Middle East and Africa
    • K.S.A.
    • Egypt
    • Rest-of-Middle East and Africa

North America to Dominate the Contract Development and Manufacturing Organization (CDMO) Market (by Region)

In terms of region, North America is expected to lead the global Contract Development and Manufacturing Organization (CDMO) market, supported by its well-established pharmaceutical, biotechnology, medical-device, and life-science industries, advanced manufacturing infrastructure, high level of outsourcing, and strong presence of global CDMO companies. The U.S. represents the largest country-level market due to its extensive drug-development pipeline, concentration of pharmaceutical and medical-device companies, advanced biologics and sterile-manufacturing capabilities, and established regulatory and quality infrastructure.

The region's growth is also supported by investments in domestic manufacturing, supply-chain resilience, advanced therapies, biologics, sterile fill-finish, and medical-device production. Asia-Pacific is expected to register the highest growth during the forecast period due to expanding pharmaceutical and medical-device manufacturing capacity, cost-competitive production, investment in biologics and advanced technologies, and the increasing presence of regional and international CDMOs across China, India, Japan, South Korea, Australia, and other regional markets.

Recent Developments in the Contract Development and Manufacturing Organization (CDMO) Market

  • In June 2026, AGC Inc. announced an integrated U.S. offering combining biologics drug-substance manufacturing with sterile fill-finish services. The offering supports liquid and lyophilized vials, prefilled syringes, cartridges, device assembly, labeling, and secondary packaging.
  • In July 2026, Lonza entered multiple customer licensing agreements covering its linker-payload and bioconjugation technologies. The agreements expanded customer access to its antibody-drug conjugate development platform for single-target, multi-target, and dual-payload therapeutic programs.
  • In April 2026, Quasar Medical opened an additional manufacturing facility in Chonburi, Thailand. The facility expanded capacity for catheter systems, balloon technologies, micro-sensor products, complex assemblies, and finished medical devices while strengthening its geographic manufacturing network.

Demand - Drivers, Challenges, and Opportunities

Market Drivers

Commercial Biologics Volumes and Late-Stage Progression Sustaining Drug-Substance, Analytical Testing, and Sterile Fill-Finish Orders: The expanding commercial base of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and other large-molecule therapies is generating recurring demand for CDMO services. As biologics advance into late-stage clinical development, process-performance qualification, regulatory approval, and commercial supply, sponsors require validated cell-culture and purification processes, comparability studies, analytical testing, stability programs, clinical and commercial drug-substance manufacturing, sterile fill-finish, and packaging. Increasing product approvals, indication expansion, geographic launches, and additional dosage presentations are expected to sustain long-term manufacturing and testing contracts.

Market Challenges

Quality-System Failures and Regulatory Remediation Interrupting Batch Release and Deferring CDMO Revenue: Quality-system failures remain a major challenge for the CDMO market because revenue depends on both manufacturing output and complete evidence that facilities, processes, equipment, personnel, and products meet applicable regulatory standards. Deficiencies in contamination control, investigations, equipment qualification, environmental monitoring, data integrity, or manufacturing records can place batches on hold, delay release, require repeat production, and prevent facilities from accepting new projects. Remediation can consume manufacturing capacity, increase testing and consulting expenses, delay milestone payments, and cause customers to transfer future projects to alternative suppliers.

Market Opportunities

Advanced-Therapy Commercialization Could Convert Underutilized Cell, Gene, and Viral-Vector Capacity into Recurring CDMO Revenue: The commercialization of cell therapies, gene therapies, viral-vector products, plasmid DNA, and other advanced therapeutic modalities presents a significant opportunity for the CDMO market. Current advanced-therapy programs generate development and clinical-manufacturing demand, but uneven pipeline progression and product-specific manufacturing processes have resulted in underutilized capacity at certain facilities. As more products progress into process validation, commercial manufacturing, regulatory inspection, and continuing analytical release, CDMOs could generate recurring revenue from vector production, cell processing, analytical development, potency testing, clinical manufacturing, aseptic processing, cryopreservation, batch release, and chain-of-identity management.

How can this report add value to an organization?

Product/Innovation Strategy: The global contract development and manufacturing organization market has been divided into several key segments, including service, product type, application, end user, and regional markets. By understanding demand across pharmaceutical development and manufacturing services, medical-device engineering and manufacturing services, small molecules, biologics, therapeutic and diagnostic devices, and life-science tools, this report offers valuable insights for organizations seeking to refine their service and innovation strategies.

Growth/Marketing Strategy: Increasing pharmaceutical and medical-device outsourcing, expanding biologics and advanced-therapy pipelines, rising demand for sterile fill-finish, growth in high-potency and antibody-drug conjugate programs, medical-device miniaturization, drug-device combination products, regional manufacturing expansion, and supply-chain diversification are anticipated to be central to the growth of the CDMO market. Key developments among pharmaceutical CDMOs, medical-device manufacturers, biotechnology companies, and product sponsors are shaping demand across development, clinical manufacturing, commercial production, and lifecycle support.

Competitive Strategy: The CDMO market is competitive and capability-driven, with large integrated providers and specialized companies competing through service breadth, technical expertise, regulatory compliance, manufacturing scale, geographic footprint, quality performance, technology-transfer speed, supply-chain reliability, and manufacturing flexibility. Key market players are strengthening their positions through acquisitions, strategic partnerships, capacity expansion, digital manufacturing, automation, single-use technologies, modular facilities, and integrated development-to-commercialization offerings.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

  • Years from 2024 to 2036 have been considered for the global market size estimation; 2025 has been considered as the base year, and 2026 to 2036 as the forecast period.
  • The scope of the report is based on comprehensive inputs from industry experts and key stakeholders across the pharmaceutical, biotechnology, medical-device, life-science, and CDMO ecosystem, including contract development and manufacturing organizations, pharmaceutical and biotechnology companies, medical-device companies, raw-material and component suppliers, packaging and sterile fill-finish service providers, analytical testing and quality service providers, and academic and research institutions.
  • Revenues from companies have been sourced from their annual reports for FY2024 and FY2025. For private companies, revenue estimates have been derived from primary research inputs, funding history, market collaborations, and operational performance.
  • The market has been mapped based on the existing contract development and manufacturing services offered across the pharmaceutical, biotechnology, medical-device, and life-science industries. Key companies with significant pharmaceutical and medical-device development and manufacturing capabilities have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts and key stakeholders across the pharmaceutical, biotechnology, medical-device, and contract development and manufacturing organization ecosystem, including CDMOs, pharmaceutical and biotechnology companies, medical-device companies, raw-material and component suppliers, packaging and fill-finish service providers, and analytical-testing and quality-service providers. Respondents such as CEOs, vice presidents, business-development directors, commercial heads, manufacturing and operations heads, research and development heads, quality and regulatory-affairs leaders, procurement heads, and supply-chain executives have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

  • validation and triangulation of all the numbers and graphs
  • validation of report segmentations and key qualitative findings
  • understanding the competitive landscape and business model
  • current and proposed production values of a product by market players
  • validation of the numbers of different segments of the market in focus
  • percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
  • Annual reports, SEC filings, and investors' presentations of the leading market players
  • Company websites and a detailed study of their product portfolio
  • Gold standard magazines, journals, white papers, press releases, and news articles
  • Paid databases

The key data points taken from the secondary sources include:

  • segmentations and percentage shares
  • data for market value
  • key industry trends of the top players in the market
  • qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Lonza
  • Thermo Fisher Scientific Inc.
  • Catalent, Inc.
  • Samsung Biologics
  • Boehringer Ingelheim International GmbH
  • Recipharm AB
  • Siegfried Holding AG
  • Piramal Pharma Limited
  • CordenPharma
  • AGC Inc.
  • Molex
  • Integer Holdings Corporation
  • Jabil Inc.
  • Sanmina Corporation
  • Quasar Medical

Table of Contents

Executive Summary

Scope and Definition

1 Global Contract Development and Manufacturing Organization (CDMO) Market: Industry Outlook

  • 1.1 Market Overview and Ecosystem
    • 1.1.1 Introduction
    • 1.1.2 Evolution of Outsourcing
    • 1.1.3 Role of CDMOs in the Value Chain
  • 1.2 Market Trends
    • 1.2.1 Trends: Current and Future Impact Assessment
      • 1.2.1.1 Impact Analysis
        • 1.2.1.1.1 Shift toward Integrated End-to-End CDMO Platforms Supported by Longer-Term Contract Structures
        • 1.2.1.1.2 Dual-Sourced Regional Networks Adopting Modular and Flexible Manufacturing Configurations
        • 1.2.1.1.3 AI-Enabled Automation and Digital Twins Moving CDMO Manufacturing and Technology Transfer toward Predictive Operations
        • 1.2.1.1.4 Miniaturization and System Integration Expanding Medtech and Diagnostics CDMO Capabilities
  • 1.3 Supply Chain Analysis
  • 1.4 Regulatory Landscape
    • 1.4.1 North America
      • 1.4.1.1 U.S.
      • 1.4.1.2 Canada
    • 1.4.2 Europe
      • 1.4.2.1 EU Countries
      • 1.4.2.2 U.K.
    • 1.4.3 Asia-Pacific
      • 1.4.3.1 Japan
      • 1.4.3.2 China
      • 1.4.3.3 Australia
      • 1.4.3.4 South Korea
    • 1.4.4 Latin America
      • 1.4.4.1 Brazil
      • 1.4.4.2 Mexico
    • 1.4.5 Middle East and Africa
      • 1.4.5.1 KSA
      • 1.4.5.2 Egypt
  • 1.5 Market Dynamics
    • 1.5.1 Market Drivers
      • 1.5.1.1 Commercial Biologics Volumes and Late-Stage Progression Sustaining Drug-Substance, Analytical Testing, and Sterile Fill-Finish Orders
      • 1.5.1.2 GLP-1 and Other Peptide Programs Generating Multi-Year Drug-Substance, Formulation, and Finished-Dose Contracts
      • 1.5.1.3 HPAPI, ADC, and Complex Small-Molecule Programs Expanding High-Value Synthesis, Analytical Testing, and Bioconjugation Orders
      • 1.5.1.4 Medtech OEM Outsourcing Sustaining Development and Manufacturing Revenue across Therapeutic and Diagnostic Devices
    • 1.5.2 Market Restraints
      • 1.5.2.1 Biotech Funding Constraints and Sponsor Pipeline Reprioritization Delaying Project Awards and Reducing CDMO Utilization
      • 1.5.2.2 Quality-System Failures and Regulatory Remediation Interrupting Batch Release and Deferring CDMO Revenue
      • 1.5.2.3 Specialized Capacity-Demand Imbalances Depressing Utilization and Increasing Fixed-Cost Pressure
    • 1.5.3 Market Opportunities
      • 1.5.3.1 Advanced-Therapy Commercialization Could Convert Underutilized Cell, Gene, and Viral-Vector Capacity into Recurring CDMO Revenue
      • 1.5.3.2 Regional Radiopharmaceutical Networks Could Expand Isotope-Linked Development, Aseptic Manufacturing, and Time-Critical Distribution Services
      • 1.5.3.3 Pharmaceutical Localization Programs Could Create New CDMO Demand in Underpenetrated Middle East and Latin America Markets
      • 1.5.3.4 Integrated Drug-Device Combination Programs Could Expand Cross-Segment Development and Manufacturing Contracts

2 Global Contract Development and Manufacturing Organization (CDMO) Market (by Service), $Billion, 2024-2036

  • 2.1 Pharmaceutical CDMO Services
    • 2.1.1 Market Sizing and Forecast
    • 2.1.2 Pharmaceutical Contract Development Services
      • 2.1.2.1 Market Sizing and Forecast
      • 2.1.2.2 Pre-Formulation and Formulation Development
      • 2.1.2.3 Market Sizing and Forecast
      • 2.1.2.4 Process Development and Optimization
      • 2.1.2.5 Market Sizing and Forecast
      • 2.1.2.6 Analytical Stability and Release Testing
      • 2.1.2.7 Market Sizing and Forecast
    • 2.1.3 Pharmaceutical Contract Manufacturing Services
      • 2.1.3.1 Market Sizing and Forecast
      • 2.1.3.2 Clinical-Scale Manufacturing
      • 2.1.3.3 Market Sizing and Forecast
      • 2.1.3.4 Commercial-Scale Manufacturing
      • 2.1.3.5 Market Sizing and Forecast
      • 2.1.3.6 Sterile Fill-Finish
      • 2.1.3.7 Market Sizing and Forecast
      • 2.1.3.8 Pharmaceutical Packaging and Labeling
      • 2.1.3.9 Market Sizing and Forecast
  • 2.2 Medical Device CDMO Services
    • 2.2.1 Market Sizing and Forecast
    • 2.2.2 Medical Device Contract Development Services
      • 2.2.2.1 Market Sizing and Forecast
      • 2.2.2.2 Product Design and Engineering
        • 2.2.2.2.1 Market Sizing and Forecast
      • 2.2.2.3 Prototyping and Design Verification
        • 2.2.2.3.1 Market Sizing and Forecast
      • 2.2.2.4 Process Development and Manufacturing Engineering
        • 2.2.2.4.1 Market Sizing and Forecast
      • 2.2.2.5 Design Verification, Testing and Validation
        • 2.2.2.5.1 Market Sizing and Forecast
    • 2.2.3 Medical Device Contract Manufacturing Services
      • 2.2.3.1 Market Sizing and Forecast
      • 2.2.3.2 Component Manufacturing
        • 2.2.3.2.1 Market Sizing and Forecast
      • 2.2.3.3 Device Assembly and Integration
        • 2.2.3.3.1 Market Sizing and Forecast
      • 2.2.3.4 Finished-Device Manufacturing
        • 2.2.3.4.1 Market Sizing and Forecast
      • 2.2.3.5 Packaging
        • 2.2.3.5.1 Market Sizing and Forecast
  • 2.3 Others
    • 2.3.1 Market Sizing and Forecast

3 Global Contract Development and Manufacturing Organization (CDMO) Market (by Product Type), $Billion, 2024-2036

  • 3.1 Pharmaceuticals
    • 3.1.1 Market Sizing and Forecast
    • 3.1.2 Small Molecules
      • 3.1.2.1 Market Sizing and Forecast
    • 3.1.3 Biologics
      • 3.1.3.1 Market Sizing and Forecast
  • 3.2 Medical Devices
    • 3.2.1 Market Sizing and Forecast
    • 3.2.2 Surgical and Interventional Devices
      • 3.2.2.1 Market Sizing and Forecast
    • 3.2.3 Implantable Medical Devices
      • 3.2.3.1 Market Sizing and Forecast
    • 3.2.4 In-Vitro Diagnostics (IVD) Devices
      • 3.2.4.1 Market Sizing and Forecast
    • 3.2.5 Drug Delivery Devices
      • 3.2.5.1 Market Sizing and Forecast
    • 3.2.6 Patient Monitoring and Diagnostic Devices
      • 3.2.6.1 Market Sizing and Forecast
  • 3.3 Others
    • 3.3.1 Market Sizing and Forecast

4 Global Contract Development and Manufacturing Organization (CDMO) Market (by Application), $Billion, 2024-2036

  • 4.1 Pharmaceuticals
    • 4.1.1 Market Sizing and Forecast
    • 4.1.2 Oncology
      • 4.1.2.1 Market Sizing and Forecast
    • 4.1.3 Infectious Disease
      • 4.1.3.1 Market Sizing and Forecast
    • 4.1.4 Cardiovascular Diseases
      • 4.1.4.1 Market Sizing and Forecast
    • 4.1.5 Neurology
      • 4.1.5.1 Market Sizing and Forecast
    • 4.1.6 Metabolic Disorders
      • 4.1.6.1 Market Sizing and Forecast
    • 4.1.7 Immunology
      • 4.1.7.1 Market Sizing and Forecast
    • 4.1.8 Rare Diseases
      • 4.1.8.1 Market Sizing and Forecast
    • 4.1.9 Others
      • 4.1.9.1 Market Sizing and Forecast
  • 4.2 Medical Devices
    • 4.2.1 Market Sizing and Forecast
    • 4.2.2 Cardiovascular
      • 4.2.2.1 Market Sizing and Forecast
    • 4.2.3 Orthopedics
      • 4.2.3.1 Market Sizing and Forecast
    • 4.2.4 Diabetes
      • 4.2.4.1 Market Sizing and Forecast
    • 4.2.5 Neurology
      • 4.2.5.1 Market Sizing and Forecast
    • 4.2.6 Gastroenterology
      • 4.2.6.1 Market Sizing and Forecast
    • 4.2.7 Oncology
      • 4.2.7.1 Market Sizing and Forecast
    • 4.2.8 Ophthalmology
      • 4.2.8.1 Market Sizing and Forecast
    • 4.2.9 Others
      • 4.2.9.1 Market Sizing and Forecast
  • 4.3 Others Application
    • 4.3.1 Market Sizing and Forecast

5 Global Contract Development and Manufacturing Organization (CDMO) Market (by End User), $Billion, 2024-2036

  • 5.1 Academic and Research Institutes
    • 5.1.1 Market Sizing and Forecast
  • 5.2 Pharmaceutical Companies
    • 5.2.1 Market Sizing and Forecast
  • 5.3 Biotechnology Companies
    • 5.3.1 Market Sizing and Forecast
  • 5.4 Medical Device Companies
    • 5.4.1 Market Sizing and Forecast
  • 5.5 Other End Users
    • 5.5.1 Market Sizing and Forecast

6 Global Contract Development and Manufacturing Organization (CDMO) Market (by Region), $Billion, 2024-2036

  • 6.1 Regional Summary
  • 6.2 North America
    • 6.2.1 Regional Overview
    • 6.2.2 Driving Factors for Market Growth
    • 6.2.3 Factors Challenging the Market
    • 6.2.4 Analyst View
    • 6.2.5 Market Sizing and Forecast
      • 6.2.5.1 North America Contract Development and Manufacturing Organization (CDMO) Market, by Country
        • 6.2.5.1.1 U.S.
          • 6.2.5.1.1.1 Country Overview
          • 6.2.5.1.1.2 Driving Factors for Market Growth
          • 6.2.5.1.1.3 Factors Challenging the Market
          • 6.2.5.1.1.4 Analyst View
          • 6.2.5.1.1.5 Market Sizing and Forecast
        • 6.2.5.1.2 Canada
          • 6.2.5.1.2.1 Country Overview
          • 6.2.5.1.2.2 Driving Factors for Market Growth
          • 6.2.5.1.2.3 Factors Challenging the Market
          • 6.2.5.1.2.4 Analyst View
          • 6.2.5.1.2.5 Market Sizing and Forecast
  • 6.3 Europe
    • 6.3.1 Regional Overview
    • 6.3.2 Driving Factors for Market Growth
    • 6.3.3 Factors Challenging the Market
    • 6.3.4 Analyst View
    • 6.3.5 Market Sizing and Forecast
      • 6.3.5.1 Europe Contract Development and Manufacturing Organization (CDMO) Market, by Country
        • 6.3.5.1.1 Germany
          • 6.3.5.1.1.1 Country Overview
          • 6.3.5.1.1.2 Driving Factors for Market Growth
          • 6.3.5.1.1.3 Factors Challenging the Market
          • 6.3.5.1.1.4 Analyst View
          • 6.3.5.1.1.5 Market Sizing and Forecast
        • 6.3.5.1.2 France
          • 6.3.5.1.2.1 Country Overview
          • 6.3.5.1.2.2 Driving Factors for Market Growth
          • 6.3.5.1.2.3 Factors Challenging the Market
          • 6.3.5.1.2.4 Analyst View
          • 6.3.5.1.2.5 Market Sizing and Forecast
        • 6.3.5.1.3 U.K.
          • 6.3.5.1.3.1 Country Overview
          • 6.3.5.1.3.2 Driving Factors for Market Growth
          • 6.3.5.1.3.3 Factors Challenging the Market
          • 6.3.5.1.3.4 Analyst View
          • 6.3.5.1.3.5 Market Sizing and Forecast
        • 6.3.5.1.4 Italy
          • 6.3.5.1.4.1 Country Overview
          • 6.3.5.1.4.2 Driving Factors for Market Growth
          • 6.3.5.1.4.3 Factors Challenging the Market
          • 6.3.5.1.4.4 Analyst View
          • 6.3.5.1.4.5 Market Sizing and Forecast
        • 6.3.5.1.5 Spain
          • 6.3.5.1.5.1 Country Overview
          • 6.3.5.1.5.2 Driving Factors for Market Growth
          • 6.3.5.1.5.3 Factors Challenging the Market
          • 6.3.5.1.5.4 Analyst View
          • 6.3.5.1.5.5 Market Sizing and Forecast
        • 6.3.5.1.6 Rest-of-Europe
          • 6.3.5.1.6.1 Country Overview
          • 6.3.5.1.6.2 Driving Factors for Market Growth
          • 6.3.5.1.6.3 Factors Challenging the Market
          • 6.3.5.1.6.4 Analyst View
          • 6.3.5.1.6.5 Market Sizing and Forecast
  • 6.4 Asia-Pacific
    • 6.4.1 Regional Overview
    • 6.4.2 Driving Factors for Market Growth
    • 6.4.3 Factors Challenging the Market
    • 6.4.4 Analyst View
    • 6.4.5 Market Sizing and Forecast
      • 6.4.5.1 Asia-Pacific Contract Development and Manufacturing Organization (CDMO) Market, by Country
      • 6.4.5.2 China
        • 6.4.5.2.1 Country Overview
        • 6.4.5.2.2 Driving Factors for Market Growth
        • 6.4.5.2.3 Factors Challenging the Market
        • 6.4.5.2.4 Analyst View
        • 6.4.5.2.5 Market Sizing and Forecast
      • 6.4.5.3 India
        • 6.4.5.3.1 Country Overview
        • 6.4.5.3.2 Driving Factors for Market Growth
        • 6.4.5.3.3 Factors Challenging the Market
        • 6.4.5.3.4 Analyst View
        • 6.4.5.3.5 Market Sizing and Forecast
      • 6.4.5.4 Japan
        • 6.4.5.4.1 Country Overview
        • 6.4.5.4.2 Driving Factors for Market Growth
        • 6.4.5.4.3 Factors Challenging the Market
        • 6.4.5.4.4 Analyst View
        • 6.4.5.4.5 Market Sizing and Forecast
      • 6.4.5.5 South Korea
        • 6.4.5.5.1 Country Overview
        • 6.4.5.5.2 Driving Factors for Market Growth
        • 6.4.5.5.3 Factors Challenging the Market
        • 6.4.5.5.4 Analyst View
        • 6.4.5.5.5 Market Sizing and Forecast
      • 6.4.5.6 Australia
        • 6.4.5.6.1 Country Overview
        • 6.4.5.6.2 Driving Factors for Market Growth
        • 6.4.5.6.3 Factors Challenging the Market
        • 6.4.5.6.4 Analyst View
        • 6.4.5.6.5 Market Sizing and Forecast
      • 6.4.5.7 Rest-of-Asia-Pacific
        • 6.4.5.7.1 Country Overview
        • 6.4.5.7.2 Driving Factors for Market Growth
        • 6.4.5.7.3 Factors Challenging the Market
        • 6.4.5.7.4 Analyst View
        • 6.4.5.7.5 Market Sizing and Forecast
  • 6.5 Latin America
    • 6.5.1 Regional Overview
    • 6.5.2 Driving Factors for Market Growth
    • 6.5.3 Factors Challenging the Market
    • 6.5.4 Analyst View
    • 6.5.5 Market Sizing and Forecast
      • 6.5.5.1 Latin America Contract Development and Manufacturing Organization (CDMO) Market, by Country
      • 6.5.5.2 Brazil
        • 6.5.5.2.1 Country Overview
        • 6.5.5.2.2 Driving Factors for Market Growth
        • 6.5.5.2.3 Factors Challenging the Market
        • 6.5.5.2.4 Analyst View
        • 6.5.5.2.5 Market Sizing and Forecast
      • 6.5.5.3 Mexico
        • 6.5.5.3.1 Country Overview
        • 6.5.5.3.2 Driving Factors for Market Growth
        • 6.5.5.3.3 Factors Challenging the Market
        • 6.5.5.3.4 Analyst View
        • 6.5.5.3.5 Market Sizing and Forecast
      • 6.5.5.4 Rest-of-Latin America
        • 6.5.5.4.1 Country Overview
        • 6.5.5.4.2 Driving Factors for Market Growth
        • 6.5.5.4.3 Factors Challenging the Market
        • 6.5.5.4.4 Analyst View
        • 6.5.5.4.5 Market Sizing and Forecast
  • 6.6 Middle East and Africa
    • 6.6.1 Regional Overview
    • 6.6.2 Driving Factors for Market Growth
    • 6.6.3 Factors Challenging the Market
    • 6.6.4 Analyst View
    • 6.6.5 Market Sizing and Forecast
      • 6.6.5.1 Middle East & Africa Contract Development and Manufacturing Organization (CDMO) Market, by Country
    • 6.6.6 KSA
      • 6.6.6.1 Regional Overview
      • 6.6.6.2 Driving Factors for Market Growth
      • 6.6.6.3 Factors Challenging the Market
      • 6.6.6.4 Analyst View
      • 6.6.6.5 Market Sizing and Forecast
    • 6.6.7 Egypt
      • 6.6.7.1 Regional Overview
      • 6.6.7.2 Driving Factors for Market Growth
      • 6.6.7.3 Factors Challenging the Market
      • 6.6.7.4 Analyst View
      • 6.6.7.5 Market Sizing and Forecast
    • 6.6.8 Rest-of-Middle East and Africa
      • 6.6.8.1 Regional Overview
      • 6.6.8.2 Driving Factors for Market Growth
      • 6.6.8.3 Factors Challenging the Market
      • 6.6.8.4 Analyst View
      • 6.6.8.5 Market Sizing and Forecast

7 Competitive Benchmarking and Company Profiles

  • 7.1 Key Strategies and Developments
  • 7.2 Company Profiles
    • 7.2.1 Lonza
      • 7.2.1.1 Overview
      • 7.2.1.2 Top Services/Service Portfolio
      • 7.2.1.3 Target Customers/End-User
      • 7.2.1.4 Key Personnel
      • 7.2.1.5 Analyst View
    • 7.2.2 Thermo Fisher Scientific Inc.
      • 7.2.2.1 Overview
      • 7.2.2.2 Top Services/Service Portfolio
      • 7.2.2.3 Target Customers/End-User
      • 7.2.2.4 Key Personnel
      • 7.2.2.5 Analyst View
    • 7.2.3 Catalent, Inc.
      • 7.2.3.1 Overview
      • 7.2.3.2 Top Services/Service Portfolio
      • 7.2.3.3 Target Customers/End-User
      • 7.2.3.4 Key Personnel
      • 7.2.3.5 Analyst View
    • 7.2.4 Samsung Biologics
      • 7.2.4.1 Overview
      • 7.2.4.2 Top Services/Service Portfolio
      • 7.2.4.3 Target Customers/End-User
      • 7.2.4.4 Key Personnel
      • 7.2.4.5 Analyst View
    • 7.2.5 Boehringer Ingelheim GmbH
      • 7.2.5.1 Overview
      • 7.2.5.2 Top Services/Service Portfolio
      • 7.2.5.3 Target Customers/End-User
      • 7.2.5.4 Key Personnel
      • 7.2.5.5 Analyst View
    • 7.2.6 Recipharm AB
      • 7.2.6.1 Overview
      • 7.2.6.2 Top Services/Service Portfolio
      • 7.2.6.3 Target Customers/End-User
      • 7.2.6.4 Key Personnel
      • 7.2.6.5 Analyst View
    • 7.2.7 Siegfried Holding AG
      • 7.2.7.1 Overview
      • 7.2.7.2 Top Services/Service Portfolio
      • 7.2.7.3 Target Customers/End-User
      • 7.2.7.4 Key Personnel
      • 7.2.7.5 Analyst View
    • 7.2.8 Piramal Pharma Limited
      • 7.2.8.1 Overview
      • 7.2.8.2 Top Services/Service Portfolio
      • 7.2.8.3 Target Customers/End-User
      • 7.2.8.4 Key Personnel
      • 7.2.8.5 Analyst View
    • 7.2.9 CordenPharma
      • 7.2.9.1 Overview
      • 7.2.9.2 Top Services/Service Portfolio
      • 7.2.9.3 Target Customers/End-User
      • 7.2.9.4 Key Personnel
      • 7.2.9.5 Analyst View
    • 7.2.10 AGC Group
      • 7.2.10.1 Overview
      • 7.2.10.2 Top Services/Service Portfolio
      • 7.2.10.3 Target Customers/End-User
      • 7.2.10.4 Key Personnel
      • 7.2.10.5 Analyst View
    • 7.2.11 Molex
      • 7.2.11.1 Overview
      • 7.2.11.2 Top Services/Service Portfolio
      • 7.2.11.3 Target Customers/End-User
      • 7.2.11.4 Key Personnel
      • 7.2.11.5 Analyst View
    • 7.2.12 Integer Holdings Corporation
      • 7.2.12.1 Overview
      • 7.2.12.2 Top Services/Service Portfolio
      • 7.2.12.3 Target Customers/End-User
      • 7.2.12.4 Key Personnel
      • 7.2.12.5 Analyst View
    • 7.2.13 Jabil Inc.
      • 7.2.13.1 Overview
      • 7.2.13.2 Top Services/Service Portfolio
      • 7.2.13.3 Target Customers/End-User
      • 7.2.13.4 Key Personnel
      • 7.2.13.5 Analyst View
    • 7.2.14 Sanmina Corporation
      • 7.2.14.1 Overview
      • 7.2.14.2 Top Services/Service Portfolio
      • 7.2.14.3 Target Customers/End-User
      • 7.2.14.4 Key Personnel
      • 7.2.14.5 Analyst View
    • 7.2.15 Quasar
      • 7.2.15.1 Overview
      • 7.2.15.2 Top Services/Service Portfolio
      • 7.2.15.3 Target Customers/End-User
      • 7.2.15.4 Key Personnel
      • 7.2.15.5 Analyst View

8 Research Methodology

  • 8.1 Data Sources
    • 8.1.1 Primary Data Sources
    • 8.1.2 Secondary Data Sources
    • 8.1.3 Data Triangulation
  • 8.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Global Contract Development and Manufacturing Organization (CDMO) Market (by Scenario), $Billion, 2026, 2031, and 2036
  • Figure 2: Global Contract Development and Manufacturing Organization (CDMO) Market (by Region), $Billion, 2025, 2031, 2036
  • Figure 3: Global Contract Development and Manufacturing Organization (CDMO) Market (by Service), $Billion, 2025, 2031, and 2036
  • Figure 4: Global Contract Development and Manufacturing Organization (CDMO) Market (by Pharmaceuticals), $Billion, 2025, 2031, and 2036
  • Figure 5: Global Contract Development and Manufacturing Organization (CDMO) Market (by Pharmaceuticals), $Billion, 2025, 2031, and 2036
  • Figure 6: Global Contract Development and Manufacturing Organization (CDMO) Market (by End User), $Billion, 2025, 2031, and 2036
  • Figure 7: Supply Chain Analysis
  • Figure 8: Global Contract Development and Manufacturing Organization (CDMO) Market (by Service), $Billion, 2025, 2031, and 2036
  • Figure 9: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceutical CDMO Services), $Billion, 2024-2036
  • Figure 10: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceutical Contract Development Services), $Billion, 2024-2036
  • Figure 11: Global Contract Development and Manufacturing Organization (CDMO) Market (Pre-Formulation and Formulation Development), $Billion, 2024-2036
  • Figure 12: Global Contract Development and Manufacturing Organization (CDMO) Market (Process Development and Optimization), $Billion, 2024-2036
  • Figure 13: Global Contract Development and Manufacturing Organization (CDMO) Market (Analytical Stability and Release Testing), $Billion, 2024-2036
  • Figure 14: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceutical Contract Manufacturing Services), $Billion, 2024-2036
  • Figure 15: Global Contract Development and Manufacturing Organization (CDMO) Market (Clinical-Scale Manufacturing), $Billion, 2024-2036
  • Figure 16: Global Contract Development and Manufacturing Organization (CDMO) Market (Commercial-Scale Manufacturing), $Billion, 2024-2036
  • Figure 17: Global Contract Development and Manufacturing Organization (CDMO) Market (Sterile Fill-Finish), $Billion, 2024-2036
  • Figure 18: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceutical Packaging and Labeling), $Billion, 2024-2036
  • Figure 19: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Device CDMO Services), $Billion, 2024-2036
  • Figure 20: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Device Contract Development Services), $Billion, 2024-2036
  • Figure 21: Global Contract Development and Manufacturing Organization (CDMO) Market (Product Design and Engineering), $Billion, 2024-2036
  • Figure 22: Global Contract Development and Manufacturing Organization (CDMO) Market (Prototyping and Design Verification), $Billion, 2024-2036
  • Figure 23: Global Contract Development and Manufacturing Organization (CDMO) Market (Process Development and Manufacturing Engineering), $Billion, 2024-2036
  • Figure 24: Global Contract Development and Manufacturing Organization (CDMO) Market (Design Verification, Testing and Validation), $Billion, 2024-2036
  • Figure 25: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Device Contract Manufacturing Services), $Billion, 2024-2036
  • Figure 26: Global Contract Development and Manufacturing Organization (CDMO) Market (Component Manufacturing), $Billion, 2024-2036
  • Figure 27: Global Contract Development and Manufacturing Organization (CDMO) Market (Device Assembly and Integration), $Billion, 2024-2036
  • Figure 28: Global Contract Development and Manufacturing Organization (CDMO) Market (Finished-Device Manufacturing), $Billion, 2024-2036
  • Figure 29: Global Contract Development and Manufacturing Organization (CDMO) Market (Packaging), $Billion, 2024-2036
  • Figure 30: Global Contract Development and Manufacturing Organization (CDMO) Market (Others), $Billion, 2024-2036
  • Figure 31: Global Contract Development and Manufacturing Organization (CDMO) Market (by Product Type), $Billion, 2025, 2031, and 2036
  • Figure 32: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceuticals), $Billion, 2024-2036
  • Figure 33: Global Contract Development and Manufacturing Organization (CDMO) Market (Small Molecules), $Billion, 2024-2036
  • Figure 34: Global Contract Development and Manufacturing Organization (CDMO) Market (Biologics), $Billion, 2024-2036
  • Figure 35: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Devices), $Billion, 2024-2036
  • Figure 36: Global Contract Development and Manufacturing Organization (CDMO) Market (Surgical and Interventional Devices), $Billion, 2024-2036
  • Figure 37: Global Contract Development and Manufacturing Organization (CDMO) Market (Implantable Medical Devices), $Billion, 2024-2036
  • Figure 38: Global Contract Development and Manufacturing Organization (CDMO) Market (In-Vitro Diagnostics (IVD) Devices), $Billion, 2024-2036
  • Figure 39: Global Contract Development and Manufacturing Organization (CDMO) Market (Drug Delivery Devices), $Billion, 2024-2036
  • Figure 40: Global Contract Development and Manufacturing Organization (CDMO) Market (Patient Monitoring and Diagnostic Devices), $Billion, 2024-2036
  • Figure 41: Global Contract Development and Manufacturing Organization (CDMO) Market (Others), $Billion, 2024-2036
  • Figure 42: Global Contract Development and Manufacturing Organization (CDMO) Market (by Application), $Billion, 2025, 2031, and 2036
  • Figure 43: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceuticals), $Billion, 2024-2036
  • Figure 44: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Oncology), $Billion, 2024-2036
  • Figure 45: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Infectious Disease), $Billion, 2024-2036
  • Figure 46: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Cardiovascular Diseases), $Billion, 2024-2036
  • Figure 47: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Neurology), $Billion, 2024-2036
  • Figure 48: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Metabolic Disorders), $Billion, 2024-2036
  • Figure 49: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Immunology), $Billion, 2024-2036
  • Figure 50: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Rare Diseases), $Billion, 2024-2036
  • Figure 51: Global Contract Development and Manufacturing Organization (CDMO) Market, Pharmaceuticals, (Others), $Billion, 2024-2036
  • Figure 52: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Devices), $Billion, 2024-2036
  • Figure 53: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Cardiovascular), $Billion, 2024-2036
  • Figure 54: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Orthopedics), $Billion, 2024-2036
  • Figure 55: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Diabetes), $Billion, 2024-2036
  • Figure 56: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Neurology), $Billion, 2024-2036
  • Figure 57: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Gastroenterology), $Billion, 2024-2036
  • Figure 58: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Oncology), $Billion, 2024-2036
  • Figure 59: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Ophthalmology), $Billion, 2024-2036
  • Figure 60: Global Contract Development and Manufacturing Organization (CDMO) Market, Medical Devices, (Others), $Billion, 2024-2036
  • Figure 61: Global Contract Development and Manufacturing Organization (CDMO) Market (Others Application), $Billion, 2024-2036
  • Figure 62: Global Contract Development and Manufacturing Organization (CDMO) Market (by End User), $Billion, 2025, 2031, and 2036
  • Figure 63: Global Contract Development and Manufacturing Organization (CDMO) Market (Academic and Research Institutes), $Billion, 2024-2036
  • Figure 64: Global Contract Development and Manufacturing Organization (CDMO) Market (Pharmaceutical Companies), $Billion, 2024-2036
  • Figure 65: Global Contract Development and Manufacturing Organization (CDMO) Market (Biotechnology Companies), $Billion, 2024-2036
  • Figure 66: Global Contract Development and Manufacturing Organization (CDMO) Market (Medical Device Companies), $Billion, 2024-2036
  • Figure 67: Global Contract Development and Manufacturing Organization (CDMO) Market (Other End Users), $Billion, 2024-2036
  • Figure 68: North America Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 69: U.S. Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 70: Canada Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 71: Europe Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 72: Germany Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 73: France Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 74: U.K. Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 75: Italy Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 76: Spain Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 77: Rest-of-Europe Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 78: Asia-Pacific Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 79: China Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 80: India Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 81: Japan Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 82: South Korea Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 83: Australia Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 84: Rest-of-Asia-Pacific Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 85: Latin America Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 86: Brazil Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 87: Mexico Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 88: Rest-of-Latin America Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 89: Middle East and Africa Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 90: KSA Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 91: Egypt Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 92: Rest-of-Middle East & Africa Contract Development and Manufacturing Organization (CDMO) Market, $Billion, 2024-2036
  • Figure 93: Data Triangulation
  • Figure 94: Top-Down and Bottom-Up Approach
  • Figure 95: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Drivers, Challenges, and Opportunities: Current and Future Impact Assessment
  • Table 3: Global Contract Development and Manufacturing Organization (CDMO) Market (by Region), $Billion, 2024-2036
  • Table 4: North America Contract Development and Manufacturing Organization (CDMO) Market (by Country), $Billion, 2024-2036
  • Table 5: Europe Contract Development and Manufacturing Organization (CDMO) Market (by Country), $Billion, 2024-2036
  • Table 6: Asia-Pacific Contract Development and Manufacturing Organization (CDMO) Market (by Country), $Billion, 2024-2036
  • Table 7: Latin America Contract Development and Manufacturing Organization (CDMO) Market (by Country), $Billion, 2024-2036
  • Table 8: Middle East & Africa Contract Development and Manufacturing Organization (CDMO) Market (by Country), $Billion, 2024-2036
  • Table 9: Some of the Major Key Strategies, February-July 2026